|
KMID : 0378019870300100089
|
|
New Medical Journal
1987 Volume.30 No. 10 p.89 ~ p.94
|
|
|
Clinical Trials of Urazamide (Recover^(®)) in Patients with Chronic Liver Diseases
|
|
|
|
|
Abstract
|
|
|
The authors conducted the clinical trials of 4-amino-5-imidazol carboxamide ureidosuccinate (Urazamide) in chronic hepatitis and liver cirrhosis. Ureidosuccinate is a precursor of the nucleoproteins with a pyrimidine structure and 4-amino-t-imidazol carboxamide is a precursor of nucleoproteic acid with a puriue structure.
It was therefore felt that Urazamide(Recover®), a combination of the two substances, should promote the synthesis of ribonucleic acid in all pathologic conditions of liver.
We selected fourteen patients with chronic hepatitis and sixteen patients with liver cirrhosis, aged between 21 and 68 years and between 31 and 69 years respectively. The dose was 3 capsules daily, each capsule containing 200mg of Urazamide(Recover®).
The clinical andd laboratory evaluation was made before and 30 days after treatment.
1. Total proteins and globulins are significantly increased from 6.4±0.79g/dl to 6.5±0.74g/dl and from 3.0 ± 0.54g/dl to 3.1± 0.49g/dl respectively, but there were no remarkable changes in serum albumin and AIG ratio after 30 days´ administration of Urazamide(Recover®).
2. SGOT and SGPT showed significant improvement (p<0.01 respectively) after Urazamide(Recover® treatment. Prothrombin time is also markedly increased.
3. Alkaline phosphatase, serum cholesterol and serum bilirubin underwent positive variations after Urazamide(Recover®) treatment.
4. Blood urea nitrogen and blood glucose as well as CBC presented no significant alterations.
5. Clinical symptoms such as anorexia, dyspepsia, asthenia and postprandial drowsiness were markedly improved, beginning 2 weeks after treatment and by the end of trial almost all patients complained no persistent symptoms.
6. No adverse symptoms were found during the 30 days´ period.
It is concluded that a hepatoregenerative compound, Urazamide(Recover®) was effective in the treatment of chronic hepatic parenchymal diseases without causing adverse effects.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|